Fig. 1From: Eligibility of monoclonal antibody-based therapy for patients with severe asthma: a Canadian cross-sectional perspectiveOverlap of patients eligible for biologic therapies, based on 128 patients with severe asthma from a Canadian Allergist and Immunologist’s referral practice, using clinical trial criteria (a) and current Canadian indications (b)Back to article page